Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 37

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

360

HTML

2233

Figures (1-1)

158

Tables (1-5)

144

Sum=2895

Oct 7, 2006 (publication date) through Apr 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Oct 7, 2006; 12(37): 6017-6020
Published online Oct 7, 2006. doi: 10.3748/wjg.v12.i37.6017

Table 4 Absolute risk reduction (95%CI for differences between proportions), relative risk reduction (RRR) and number needed to treat (NNT)

Symptoms, d	Absolute risk reduction¹ (95% CI for difference in improvement) (%)	RRR (%)	NNT
Heartburn, d 28	+ 11.1 (2.7-19.4)	15	9
Acid regurgitation, d 14	+ 15.3 (5.3-25.0)	26	7
Acid regurgitation, d 28	+ 10.5 (3.6-17.5)	13	10
Bloating, d 14	+ 16.8 (5.7-27.9)	33	6
Bloating, d 28	+ 10.2 (1.4-19.0)	13	10

¹Significant differences in favor of test group were analyzed.

Citation: Pai VG, Pai NV, Thacker HP, Shinde JK, Mandora VP, Erram SS. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. World J Gastroenterol 2006; 12(37): 6017-6020
URL: https://www.wjgnet.com/1007-9327/full/v12/i37/6017.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i37.6017